Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity

MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ — VIVUS, Inc.
(NASDAQ:
VVUS) today announced that multiple abstracts will be presented
at the upcoming European Congress on Obesity meeting to be held May
25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention &
Exhibition Center in Istanbul, Turkey.  The details of the
presentations are as follows:Oral presentation:Friday, May 27
– Novel Drugs Session, Presentation time 17:15-17:30 (local
time)Authors:  

Stephan Rossner, MD, PhD; Craig A. Peterson, MS; Barbara
Troupin, MD, MBATitle:  

CARDIOMETABOLIC RISK REDUCTION IS DIRECTLY RELATED TO MAGNITUDE
OF WEIGHT LOSS WITH LOW DOSE, CONTROLLED-RELEASE
PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) [T5:RS4.4]Poster
presentations:Thursday, May 26– Hot Topic Poster Session,
Presentation time 13:00-15:00 (local time)Authors:  

George A. Bray, MD; Louis J. Aronne, MD; Alok K. Gupta, MD;
Wesley W. Day, PhD; Barbara Troupin, MD, MBATitle:  

EFFICACY AND TOLERABILITY OF TOPIRAMATE ALONE AND IN COMBINATION
WITH PHENTERMINE [HTP.025]Friday, May 27– Poster Session,
Presentation time 13:00-15:00 (local time)Authors:  

W. Timothy Garvey, MD; Craig A. Peterson, MS; Barbara Troupin,
MD, MBATitle:  

WEIGHT LOSS WITH LOW-DOSE, CONTROLLED-RELEASE
PHENTERMINE/TOPIRAMATE THERAPY IMPROVES GLYCAEMIC STATUS AND
PREVENTS PROGRESSION TO TYPE 2 DIABETES MELLITUS [T5:P.102]Authors:
 

W. Timothy Garvey, MD; Wesley W. Day, PhD, Charles H. Bowden,
MDTitle:  

LONG-TERM TREATMENT WITH CONTROLLED-RELEASE
PHENTERMINE/TOPIRAMATE DEMONSTRATES SUSTAINED WEIGHT LOSS OVER 108
WEEKS [T5:P.103]All posters will be displayed in the Exhibition
Hall from the afternoon of May 25th until the morning of May
28th.

About QNEXA Controlled Release CapsulesQNEXA
[kyoo-nek-suh] is an investigational drug c

‘/>”/>

SOURCE